Crescent Capital BDC Inc

Crescent Capital BDC Inc (CCAP) Stock Analysis

$9.640

+0.299 (+3.10%)At close

Loading chart…
High
9.720
Open
9.500
VWAP
9.62
Volume
174.07K
Mkt Cap
702.69M
Low
9.485
Amount
1.67M
EV/EBITDA, TTM
9.72

Crescent Capital BDC, Inc. is a specialty finance company focused on lending to middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It invests primarily in secured debt, including first lien, unitranche first lien and second-lien debt, and unsecured debt, including mezzanine and subordinated debt, as well as related equity securities of private United States middle-market companies. It is focused on purchasing interests in loans or making debt investments, either directly from its target companies as primary market or private credit investments (private credit transactions), or primary or secondary market bank loans or high-yield transactions in the syndicated market (syndicated loans and bonds). Although its focus is on investing in less liquid private credit transactions. The Company is managed by Crescent Cap Advisors, LLC.

AI analysis of Crescent Capital BDC Inc (CCAP)

Hold

Crescent Capital BDC Inc (CCAP) is currently priced at $9.415, which is significantly below its 52-week high of $15.18, suggesting potential upside. However, the stock has a high RSI of 75.951, indicating it may be overbought. Additionally, the forward P/E ratio is 6.7159, which is attractive, but the company recently reported a decline in net income and cut its dividend by 19%, raising concerns about its financial health. The main risk is the EPS forecast of $0.35 for the next quarter, which is lower than the previous quarter's reported EPS of $0.36, indicating ongoing challenges. Therefore, while there is potential for recovery, the current indicators suggest a cautious approach rather than a strong buy.

Valuation Metrics

The current forward P/E ratio for Crescent Capital BDC Inc (CCAP) is 6.72, compared to its 5-year average forward P/E of 8.88.

Forward P/E

Fair
5Y Average P/E
8.88
Current P/E
6.72
Overvalued
14.27
Undervalued
3.50

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
1.97
Current EV/EBITDA
9.72
Overvalued
6.43
Undervalued
-2.49

Forward P/S

Undervalued
5Y Average P/S
3.40
Current P/S
2.41
Overvalued
4.09
Undervalued
2.71

Alphio AI Price Scenarios for CCAP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CCAP

$16.82

Scenario price

B

Base

Base · 50%CCAP

$16.07

Scenario price

B

Bear

Bear · 25%CCAP

$14.23

Scenario price

Whales holding CCAP

C

Cerberus Capital Management, L.P.

+ HoldingCCAP

+6.90%

3M Return

B

Blackstone Inc.

+ HoldingCCAP

-8.84%

3M Return

F

Fidelity National Financial, Inc.

+ HoldingCCAP

-14.26%

3M Return

CCAP FAQ — answered by Alphio AI

Crescent Capital BDC, Inc. is a specialty finance company focused on lending to middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It invests primarily in secured debt, including first lien, unitranche first lien and second-lien debt, and unsecured debt, including mezzanine and subordinated debt, as well as related equity securities of private United States middle-market companies. It is focused on purchasing interests in loans or making debt investments, either directly from its target companies as primary market or private credit investments (private credit transactions), or primary or secondary market bank loans or high-yield transactions in the syndicated market (syndicated loans and bonds). Although its focus is on investing in less liquid private credit transactions. The Company is managed by Crescent Cap Advisors, LLC. It operates in the Financials sector.

Crescent Capital BDC Inc (CCAP) is currently priced at $9.415, which is significantly below its 52-week high of $15.18, suggesting potential upside. However, the stock has a high RSI of 75.951, indicating it may be overbought. Additionally, the forward P/E ratio is 6.7159, which is attractive, but the company recently reported a decline in net income and cut its dividend by 19%, raising concerns about its financial health. The main risk is the EPS forecast of $0.35 for the next quarter, which is lower than the previous quarter's reported EPS of $0.36, indicating ongoing challenges. Therefore, while there is potential for recovery, the current indicators suggest a cautious approach rather than a strong buy.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading